Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: A randomized study conducted by the hellenic cooperative oncology group

Journal of Clinical Oncology

Volumn 19, Issue 8, 2001, Pages 2232-2239

  Fountzilas, G ^a   Papadimitriou, C ^a   Dafni, U ^a   Bafaloukos, D ^a   Skarlos, D ^a   Moulopoulos, L A ^a   Razis, E ^a   Kalofonos, H P ^a   Aravantinos, G ^a   Briassoulis, E ^a   Papakostas, P ^a   Abela, K ^a   Gogas, E ^a   Kosmidis, P ^a   Pavlidis, N ^a   Dimopoulos, M A ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

EPIRUBICIN; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0035871159     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.8.2232     Document Type: Article

References (33)

1. Drugs ten years later: Epirubicin
2. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: A phase I/II trial of 96-hour infusion
3. Paclitaxel in metastatic breast cancer: A trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines
4. A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines
5. Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: A regimen with high activity and low cardiotoxicity in advanced breast cancer
6. Phase I study of paclitaxel and epirubicin in patients with metastatic breast cancer: A preliminary report on safety
7. Conceptual basis for advances in the systemic drug therapy of breast cancer
8. Dose-dense sequential chemotherapy with epirubicin and paclitaxel in advanced breast cancer
9. Concurrent or sequential use of cytotoxic chemotherapy and hormone treatment in advanced breast cancer: Report of the Swiss Group for Clinical Cancer Research
10. Toxicity and response criteria of the Eastern Cooperative Oncology Group
11. Will there be resistance to the RECIST (response evaluation criteria in solid tumors)?
12. Exact significance testing to establish treatment equivalence for ordered categorical data
13. Nonparametric estimation from incomplete observations
14. Asymptomatically efficient rank invariant test procedures
15. Regression models and life tables
16. Partial residual for the proportional hazards regression models
17. Martingale based residuals for survival models
18. CONSORT: An evolving tool to help improve the quality of reports of randomized controlled trials
19. Sequential dose-dense doxorubicin, paclitaxel and cyclophosphamide for resectable high-risk breast cancer: Feasibility and efficacy
20. Dose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel and CMF in high-risk breast cancer
21. Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group
22. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study
23. Doxorubicin and paclitaxel: Highly active combination in the treatment of metastatic breast cancer
24. Phase III trial of doxorubicin vs. paclitaxel vs. doxorubicin + paclitaxel as first line therapy for metastatic breast cancer: An Intergroup trial
25. Phase II trial of doxorubicin and paclitaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: An Eastern Cooperative Oncology Group study
26. A randomized study of epirubicin monotherapy every 4 or every 2 weeks in advanced breast cancer
27. Paclitaxel plus doxorubicin in metastatic breast cancer: The Milan experience
28. Phase III multicenter trial comparing Taxol/doxorubicin vs 5-fluorouracil, doxorubicin and cyclophosphamide as first line treatment for patients with metastatic breast cancer
29. Randomized multicenter phase III study of epirubicin/paclitaxel versus epirubicin/cyclophosphamide in first line treatment of metastatic breast cancer: A study of the AGO Breast Cancer Study Group
30. Paclitaxel by 3-hour infusion and carboplatin in anthracycline-resistant advanced breast cancer: A phase II study
31. First line chemotherapy with paclitaxel by three-hour infusion and carboplatin in advance breast cancer: Final report - A phase II study conducted by the Hellenic Cooperative Oncology Group